Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

956.53 -3.49 (-0.36%)
Official Closing Price Updated: 7:00 PM EDT, Sep 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,529,494
Open 957.77
Bid (Size) 952.30 (1)
Ask (Size) 956.00 (1)
Prev. Close 960.02
Today's Range 951.58 - 969.65
52wk Range 516.57 - 972.53
Shares Outstanding N/A
Dividend Yield 0.47%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eli Lilly Trades Near All-Time High: Check Out The IBD 50, Big Cap 20, Other Top Stock Lists
Lilly, which traces it roots in the industry back 150 years to its founding by chemist Eli Lilly, boasts a best-possible 99 Composite Rating. 
Via Investor's Business Daily
3 Big Winners From The Q2 Earnings Season: LLY, LMT, META
The 2024 Q2 earnings season is slowly grinding to a halt, with the majority of S&P 500 companies already delivering quarterly results. All three listed here posted robust results with shares of each... 
Via Talk Markets
Topics Stocks
Exposures US Equities

Performance

YTD
+61.52%
+61.52%
1 Month
+23.38%
+23.38%
3 Month
+14.89%
+14.89%
6 Month
+23.01%
+23.01%
1 Year
+71.36%
+71.36%

More News

Read More
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Via Benzinga
Topics Economy
Exposures Interest Rates
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Gilding The Lilly
Via Talk Markets
Decoding Eli Lilly's Options Activity: What's the Big Picture?
Via Benzinga
Here's How Much $1000 Invested In Eli Lilly 10 Years Ago Would Be Worth Today
Via Benzinga
Will September Bring A Rebound In Google Stock Amid New Antitrust Trial?
Via Investor's Business Daily
Eli Lilly Launches Discounted Mounjaro And Zepbound As Fight Against Compounded Imitations Escalates Amid Ongoing FDA Shortage Status Debate
Via Benzinga
Exposures Product Safety
2 No-Brainer Growth Stocks to Buy With $1,000 Right Now
Via The Motley Fool
Market Thoughts This Labor Day Weekend
Via Talk Markets
Topics Economy
Exposures Interest Rates
S&P 500 Giants Meta, Eli Lilly Lead 5 Stocks Near Buy Points
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
3 No-Brainer Stocks to Buy in September
Via The Motley Fool
These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now
Via The Motley Fool
2 Unstoppable Growth Stocks to Buy Right Now for Less Than $1,000
Via The Motley Fool
Judge's Early Ruling May Shape Outcome In Ozempic, Wegovy Lawsuits
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Novo Nordisk Touts Encouraging Wegovy Data To Lower Risk Of Severe Complications In Heart Failure Patients
Via Benzinga
Think Eli Lilly Stock Has Peaked? These 10 Words From the CEO May Change Your Mind
Via The Motley Fool
This New Finding About Ozempic and Wegovy Could Hurt Novo Nordisk's Stock
Via The Motley Fool
Why Hims & Hers Health Stock Was Falling This Week
Via The Motley Fool
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
Via Investor's Business Daily
Biotech And Life Science Sector Update Summer Of 2024
Via Talk Markets
Is Eli Lilly Stock a No-Brainer Buy After the Company's Brilliant Zepbound Move?
Via The Motley Fool
Warren Buffett's Berkshire Hathaway Breaks $1 Trillion: Poll Suggests Big Pharma, Not Tech, Is Next Contender
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.